Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 129, Issue 26
June 29 2017
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
A Richter transformation PD-1 block party
Clinical Trials & Observations
John M. Pagel
View Articletitled, A Richter transformation PD-1 block party
INSIDE BLOOD COMMENTARY
CD1d-dependent CLL progression?
Mark L. Lang
View Articletitled, CD1d-dependent CLL progression?
INSIDE BLOOD COMMENTARY
Singling out FLI1 in Paris-Trousseau syndrome
Hervé Falet
View Articletitled, Singling out FLI1 in Paris-Trousseau syndrome

BLOOD SPOTLIGHT

Midostaurin approved for FLT3-mutated AML
Clinical Trials & Observations
Mark Levis
View Articletitled, Midostaurin approved for FLT3-mutated AML

REVIEW ARTICLE

ITIM receptors: more than just inhibitors of platelet activation
Carmen H. Coxon,Mitchell J. Geer,Yotis A. Senis
View Articletitled, ITIM receptors: more than just inhibitors of platelet activation
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Clinical Trials & Observations
Wei Ding,Betsy R. LaPlant,Timothy G. Call,Sameer A. Parikh,Jose F. Leis,Rong He,Tait D. Shanafelt,Sutapa Sinha,Jennifer Le-Rademacher,Andrew L. Feldman,Thomas M. Habermann,Thomas E. Witzig,Gregory A. Wiseman,Yi Lin,Erik Asmus,Grzegorz S. Nowakowski,Michael J. Conte,Deborah A. Bowen,Casey N. Aitken,Daniel L. Van Dyke,Patricia T. Greipp,Xin Liu,Xiaosheng Wu,Henan Zhang,Charla R. Secreto,Shulan Tian,Esteban Braggio,Linda E. Wellik,Ivana Micallef,David S. Viswanatha,Huihuang Yan,Asher A. Chanan-Khan,Neil E. Kay,Haidong Dong,Stephen M. Ansell
View Articletitled, Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells
Mathew G. Angelos,Paige N. Ruh,Beau R. Webber,Robert H. Blum,Caitlin D. Ryan,Laura Bendzick,Seonhui Shim,Ashley M. Yingst,Dejene M. Tufa,Michael R. Verneris,Dan S. Kaufman
View Articletitled, Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells
Supplemental data

LYMPHOID NEOPLASIA

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis
Clinical Trials & Observations
Francesca Gorini,Laura Azzimonti,Gloria Delfanti,Lydia Scarfò,Cristina Scielzo,Maria Teresa Bertilaccio,Pamela Ranghetti,Alessandro Gulino,Claudio Doglioni,Arianna Di Napoli,Miriam Capri,Claudio Franceschi,Federico Caligaris-Cappio,Paolo Ghia,Matteo Bellone,Paolo Dellabona,Giulia Casorati,Claudia de Lalla
View Articletitled, Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis
Supplemental data
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
Michelle M. McDonald,Michaela R. Reagan,Scott E. Youlten,Sindhu T. Mohanty,Anja Seckinger,Rachael L. Terry,Jessica A. Pettitt,Marija K. Simic,Tegan L. Cheng,Alyson Morse,Lawrence M. T. Le,David Abi-Hanna,Ina Kramer,Carolyne Falank,Heather Fairfield,Irene M. Ghobrial,Paul A. Baldock,David G. Little,Michaela Kneissel,Karin Vanderkerken,J. H. Duncan Bassett,Graham R. Williams,Babatunde O. Oyajobi,Dirk Hose,Tri G. Phan,Peter I. Croucher
View Articletitled, Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma
Supplemental data

MYELOID NEOPLASIA

GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML
Parvesh Chaudhry,Mohan Singh,Timothy J. Triche,Monica Guzman,Akil A. Merchant
View Articletitled, GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Human CD62Ldim neutrophils identified as a separate subset by proteome profiling and in vivo pulse-chase labeling
Tamar Tak,Patrick Wijten,Marjolein Heeres,Peter Pickkers,Arjen Scholten,Albert J. R. Heck,Nienke Vrisekoop,Luke P. Leenen,José A. M. Borghans,Kiki Tesselaar,Leo Koenderman
View Articletitled, Human CD62L<sup>dim</sup> neutrophils identified as a separate subset by proteome profiling and in vivo pulse-chase labeling
Supplemental data

PLATELETS AND THROMBOPOIESIS

FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology
Karen K. Vo,Danuta J. Jarocha,Randolph B. Lyde,Vincent Hayes,Christopher S. Thom,Spencer K. Sullivan,Deborah L. French,Mortimer Poncz
View Articletitled, FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology
Supplemental data

LETTERS TO BLOOD

In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI
Clinical Trials & Observations
Gian Matteo Rigolin,Maurizio Cavallari,Francesca Maria Quaglia,Luca Formigaro,Enrico Lista,Antonio Urso,Emanuele Guardalben,Carmine Liberatore,Danilo Faraci,Elena Saccenti,Cristian Bassi,Laura Lupini,Maria Antonella Bardi,Eleonora Volta,Elisa Tammiso,Aurora Melandri,Massimo Negrini,Francesco Cavazzini,Antonio Cuneo
View Articletitled, In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI
Supplemental data
Platelet factor 4/heparin complexes present epitopes differently on solid-phase vs platelet surfaces
Thi-Huong Nguyen,Andreas Greinacher
View Articletitled, Platelet factor 4/heparin complexes present epitopes differently on solid-phase vs platelet surfaces
Supplemental data

BLOOD WORK

Cystic splenomegaly: ectopic adenocarcinoma of unknown primary
Clinical Trials & Observations
Muhammad Bilal Abid,Norbert Blesing
View Articletitled, Cystic splenomegaly: ectopic adenocarcinoma of unknown primary
Targeted therapy–induced differentiation of acute myeloid leukemia blasts
Andrés E. Quesada,Rashmi Kanagal-Shamanna
View Articletitled, Targeted therapy–induced differentiation of acute myeloid leukemia blasts
All Issues

Advertisement intended for health care professionals

Broken brakes: PRC loss foils menin inhibition
The promise of allosteric kinase inhibition
Endothelial inflammation: how many bad apples?
A simple score for clonal cytopenias
Are D+ units safe for D+ patients with anti-D?

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals